FRESENIUS SE+CO. ADR 1/4 (FREA) - Total Liabilities
Based on the latest financial reports, FRESENIUS SE+CO. ADR 1/4 (FREA) has total liabilities worth €21.63 Billion EUR (≈ $25.29 Billion USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore FRESENIUS SE+CO. ADR 1/4 equity growth rate to track the company's year-over-year net asset growth rate.
FRESENIUS SE+CO. ADR 1/4 - Total Liabilities Trend (2021–2025)
This chart illustrates how FRESENIUS SE+CO. ADR 1/4's total liabilities have evolved over time, based on quarterly financial data.
FRESENIUS SE+CO. ADR 1/4 Competitors by Total Liabilities
The table below lists competitors of FRESENIUS SE+CO. ADR 1/4 ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Tapestry Inc
NYSE:TPR
|
USA | $5.78 Billion |
|
DCI Indonesia Tbk PT
JK:DCII
|
Indonesia | Rp2.88 Trillion |
|
PPL Corporation
NYSE:PPL
|
USA | $24.38 Billion |
|
TechnipFMC PLC
NYSE:FTI
|
USA | $6.72 Billion |
|
Ecopetrol SA ADR
NYSE:EC
|
USA | $174.70 Trillion |
|
ACS Actividades de Construccion y Servicios SA
MC:ACS
|
Spain | €36.88 Billion |
|
Xylem Inc
NYSE:XYL
|
USA | $5.85 Billion |
|
Ningxia Baofeng Energy Group Co Ltd
SHG:600989
|
China | CN¥42.39 Billion |
Liability Composition Analysis (2021–2025)
This chart breaks down FRESENIUS SE+CO. ADR 1/4's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see FRESENIUS SE+CO. ADR 1/4 (FREA) market capitalisation.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.32 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.52 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how FRESENIUS SE+CO. ADR 1/4's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for FRESENIUS SE+CO. ADR 1/4 (2021–2025)
The table below shows the annual total liabilities of FRESENIUS SE+CO. ADR 1/4 from 2021 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €21.63 Billion ≈ $25.29 Billion |
-7.02% |
| 2024-12-31 | €23.26 Billion ≈ $27.19 Billion |
-9.26% |
| 2023-12-31 | €25.63 Billion ≈ $29.97 Billion |
-41.98% |
| 2022-12-31 | €44.18 Billion ≈ $51.65 Billion |
+3.53% |
| 2021-12-31 | €42.67 Billion ≈ $49.89 Billion |
-- |
About FRESENIUS SE+CO. ADR 1/4
Fresenius SE & Co. KGaA, a health care company, provides products and services for chronically ill patients. It operates through Fresenius Kabi and Fresenius Helios segment. The Fresenius Kabi segment engages in the therapy and care of critically and chronically ill patients; enteral and parenteral nutrition products; medical technologies, as well as disposables, infusions pumps, apheresis machin… Read more